Image Credit: Adobe Stock Images/Ustas.com
In an effort to grow its offerings across the pharma value chain, Peli BioThermal, a provider of temperature-controlled packaging and service solutions, has purchased Evo from BioLife Solutions.1
The Evo portfolio features cryogenic shippers, along with its proprietary evoIS technology platform, which primarily operates in the cell & gene therapy (CGT) field. In order to successfully deliver therapies to patients, the sector requires accuracy, reliability, and the ability to pivot.
This acquisition enhances Peli BioThermal’s ability to offer a comprehensive portfolio of cold chain solutions, expanding the options for existing clients while opening doors to new partnerships spanning the pharma, biopharma, and clinical supply sectors. Current Evo customers will benefit from greater convenience and streamlined integration by sourcing directly through Peli BioThermal. Meanwhile, the Evo product line is expected to experience greater innovation, development, and scalability, which driving greater value for more customers.
“The addition of Evo is a strategic step forward that rounds out our solutions portfolio and reinforces our commitment to solving our customers’ toughest cold chain challenges,” said Sam Herbert, CEO of Peli BioThermal. “Peli BioThermal customers will gain greater choice and convenience, while Evo customers will benefit from access to our global expertise and service network, ensuring both groups are better supported as their needs grow. BioLife Solutions, and SAVSU before that, have done a fantastic job innovating in a complex market and have been fantastic stewards of this business. In this next chapter, we will devote our substantial capabilities and further resources to expand and innovate at an accelerated pace.”
Expanding reach into high-growth end markets
The Evo lineup joins Peli BioThermal’s existing product portfolio, such as the NanoCool systems, Crēdo reusable shippers, and most recently, its Vēro One single-use dry ice shipper and Crēdo Vault bulk shipper.
“Evo will allow Peli BioThermal to offer a full spectrum of temperature-controlled solutions, which will help the company deepen its relationship with existing customers and open access to new high-growth end markets,” said Platinum Equity Co-President Jacob Kotzubei and Managing Director Matthew Louie in a joint statement. “Our commitment to investing in Peli BioThermal is creating considerable momentum right now and we are excited about the direction in which the business is headed.”
Fast facts: Peli BioThermal’s Evo acquisition
- Acquirer: Peli BioThermal, a global provider of temperature-controlled packaging and logistics solutions
- Acquired company: Evo, a BioLife Solutions brand specializing in cryogenic shipping and evoIS tracking technology
- Sector focus: Cell and gene therapy (CGT), pharma, biopharma, and clinical supply chains
- Strategic goal: Expand Peli BioThermal’s cold chain portfolio to deliver end-to-end temperature control solutions
Broader cold chain developments and industry sustainability goals
In other cold chain news, CSafe, another provider of temperature-controlled shipping solutions,has unveiled the Silverskin RE, a reusable thermal cover.2 According to the company, the product’s benefits are two-fold, providing protection while helping pharma companies meet their sustainability goals, supporting 2-8°C and +15-25°C temperature ranges.
The Silverskin RE’s materials preserve thermal performance over the course of multiple shipping cycles, and is zip-closure door is weather-resistant, while the cover has adjustable straps that can accommodate various pallet height requirements in the US and EU.
“Sustainability is a major focus for pharmaceutical companies around the world and we want to support them in achieving their goals,” explained Patrick Schafer, CSafe’s CEO. “The Silverskin RE is a great alternative to single-use thermal covers, offering the reliability CSafe is known for with the added benefit of multiple reuses that reduce waste and environmental impact.”
Further down the supply chain to the end patient, companies operating within the cold chain space must also be aware of the growing popularity of therapies and specialty products, and with that, the role direct-to-patient delivery. That comes with its share of challenges, including the fact thats patients and retail pharmacies struggle with using temperature monitors correctly.
Despite including instructions on both the box and inside the package, fewer than 30% of people activated the device properly—per Moderna stats—with many of these being shipped to CVS, Kroger’s, Sam’s Club, and Walmart.3
Reference
1. Peli BioThermal Announces Acquisition to Expand Cold Chain Logistics Solutions and Advance Cryogenic Cell and Gene Therapy Transport . PR Newswire. October 7, 2025. Accessed October 7, 2025. https://www.prnewswire.com/news-releases/peli-biothermal-announces-acquisition-to-expand-cold-chain-logistics-solutions-and-advance-cryogenic-cell-and-gene-therapy-transport-302576492.html
2. CSafe Strengthens Temperature-Controlled Portfolio with the Launch of a Reusable Thermal Cover: Silverskin RE. CSafe. October 7, 2025. Accessed October 7, 2025. Press release received via email.
3. Saraceno N. LogiPharma USA 2025: How Pharma Leaders Are Tackling Temperature Monitoring in Direct-to-Patient Shipments. Pharmaceutical Commerce. October 2, 2025. Accessed October 7, 2025. https://www.pharmaceuticalcommerce.com/view/how-pharma-leaders-tackling-temp-monitoring-direct-to-patient-shipments
